×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
FOLD – amicus therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
FOLD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
09:12 am
fold
Amicus Therapeutics (NASDAQ:FOLD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $17.00 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $17.00 price target on the stock.
12/15
02:14 am
fold
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT [Yahoo! Finance]
Low
Report
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT [Yahoo! Finance]
12/13
07:35 pm
fold
Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook [Yahoo! Finance]
Low
Report
Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook [Yahoo! Finance]
12/13
07:15 am
fold
Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy' Reco [Yahoo! Finance]
Low
Report
Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy' Reco [Yahoo! Finance]
11/28
10:23 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
11/28
08:31 am
fold
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
Low
Report
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
11/26
02:01 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
11/14
01:10 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-1.2%
amicus therapeutics, inc.
7/31/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-6.4%
amicus therapeutics, inc.
2/19/2025
07:00 am
fold
amicus therapeutics, inc.
BEAT
Report
-4.3%
amicus therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/15
04:32 pm
fold
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
Low
Report
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
12/15
04:18 pm
fold
Form 144 AMICUS THERAPEUTICS, Filed by: Clark David Michael
Low
Report
Form 144 AMICUS THERAPEUTICS, Filed by: Clark David Michael
12/3
08:11 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Dec 01 Filed by: Prout Samantha
Medium
Report
Form 4 AMICUS THERAPEUTICS, For: Dec 01 Filed by: Prout Samantha
12/3
08:11 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Dec 01 Filed by: Campbell Bradley L
Medium
Report
Form 4 AMICUS THERAPEUTICS, For: Dec 01 Filed by: Campbell Bradley L
12/3
11:13 am
fold
Form SCHEDULE 13G/A AMICUS THERAPEUTICS, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A AMICUS THERAPEUTICS, Filed by: VANGUARD GROUP INC
12/1
04:20 pm
fold
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
Low
Report
Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L
11/26
09:19 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Nov 24 Filed by: Castelli Jeff
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Nov 24 Filed by: Castelli Jeff
11/26
09:18 pm
fold
Form 4 AMICUS THERAPEUTICS, For: Nov 24 Filed by: Clark David Michael
Low
Report
Form 4 AMICUS THERAPEUTICS, For: Nov 24 Filed by: Clark David Michael
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/2
Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
8.5%
2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%
3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%
2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%
6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%
1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%
10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%
3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%
7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%
4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%
2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%
3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%
2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%
6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%
1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%
10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%
3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%
7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%
4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%
TOP News Decliners
10/3
Amicus snaps back on positive data from Pompe Disease study of AT-GAA [Seeking Alpha]
-10.0%
8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%
3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%
8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%
5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%
12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%
8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%
7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%
1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%
1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%
8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%
3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%
8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%
5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%
12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%
8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%
7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%
1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%
1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: